Evolution of the Average Target: NOV Inc.

Evolution of the Target Price: NOV Inc.

Changes in Analyst Recommendations: NOV Inc.

79b7643dbb5638a.7vYBgXhCZkLZAnrvSm8wTwFi_nuX-U7lJ_grqljUoH0.ibly-SAJAXeNTkqYHxZVeU4zx0ze1C2LFLNt2iuH4RfYpXTHLXMqd59zHQ~56d2c2d3cddfa6c256c777560cf57f80
06-04 NOV Shares Rise After Capital One Upgrade MT
06-04 Capital One Upgrades NOV to Overweight From Equal Weight, Adjusts Price Target to $26 From $25 MT
04-30 Zephirin Cuts Price Target on NOV to $17 From $18, Keeps Hold Rating, Medium Risk MT
04-29 RBC Lifts Price Target on NOV to $22 From $21, Keeps Sector Perform Rating MT
04-14 NOV Offers Upside From Improved Offshore and Short-Cycle Activity but Better Alternatives Exist, RBC Says MT
04-14 RBC Downgrades NOV to Sector Perform From Outperform, Keeps $21 Price Target MT
04-14 Analyst recommendations: Biogen, Ford, Ge Vernova, Booking, Comcast… Zonebourse
02-23 Zephirin Downgrades NOV to Hold From Buy, Lifts Price Target to $18 From $17, Keeps Medium Risk MT
02-12 Analyst recommendations: Pfizer, Applovin, Biogen, Hilton, Snap… Zonebourse
02-04 Barclays Upgrades NOV to Equalweight From Underweight, Raises Price Target to $20 From $15 MT
02-04 Analyst recommendations: Booking, PayPal, Fedex, Gartner, Lockheed Martin…. Zonebourse
01-15 RBC Capital Adjusts NOV Price Target to $21 From $19, Maintains Outperform Rating MT
01-14 Analyst recommendations: Rivian, Applied Materials, Coinbase, Intel, Spotify… Zonebourse
11-20 Zephirin Lowers Price Target on NOV to $16 From $17, Keeps Buy Rating MT
29/10/25 RBC Raises Price Target on NOV to $19 From $17, Keeps Outperform Rating MT
09/10/25 RBC Lowers Price Target on NOV to $17 From $18, Keeps Outperform Rating MT
30/07/25 RBC Cuts Price Target on NOV to $18 From $19, Keeps Outperform Rating MT
28/07/25 NOV's Q2 revenue falls but beats expectations RE
15/05/25 Zephirin Cuts Price Target on NOV to $17 From $19, Keeps Buy Rating MT
30/04/25 RBC Trims Price Target on NOV to $19 From $20, Keeps Outperform Rating MT
24/03/25 Analyst recommendations: General Mills, Ulta Beauty, Micron Technology, RH… Zonebourse
24/03/25 RBC Upgrades NOV to Outperform From Sector Perform, Maintains $22 Price Target MT
06/02/25 RBC Raises Price Target on NOV to $22 From $21, Keeps Sector Perform Rating MT
15/01/25 Evercore ISI Downgrades NOV to In Line From Outperform, Adjusts Price Target to $18 From $25 MT
06/01/25 Seaport Downgrades NOV to Neutral From Buy MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+2.7%
+11%
+12.83%
+11.72%
+7.36%
+1.08%
+19.11%
+19.01%
+27.87%
+11.67%
Average +12.43%
Weighted average by Cap. +11.38%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
21.13USD
Average target price
21.70USD
Spread / Average Target
+2.70%
High Price Target
26.00USD
Spread / Highest target
+23.05%
Low Price Target
17.00USD
Spread / Lowest Target
-19.55%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Capital One Securities
Zephirin Group
RBC Capital Markets
Barclays
Evercore ISI
Seaport Global Securities
Piper Sandler
Citigroup
Zephirin
Wells Fargo Securities
Morgan Stanley
Raymond James
TD Cowen
JPMorgan Chase
Goldman Sachs
BofA Securities
Cowen
Susquehanna
Benchmark Company
Stifel Nicolaus
UBS
Coker Palmer Institutional
ATB Capital
BMO Capital
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
21.13USD
Average target price
21.70USD
Spread / Average Target
+2.70%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!